Recruiting

Medication Treatments

Sponsor:

Anne E. Zepeski

Code:

NCT06993038

Conditions

Supraventricular Tachycardia (SVT)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

adenosine

diltiazem

Study Details

Brief summary:

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Conditions

Supraventricular Tachycardia (SVT)

Study ID

NCT06993038

Start date

Aug 1, 2025

Status verified date

May, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adult patients (18 years and older)
2. Diagnosis of acute, stable SVT in the emergency department

Exclusion Criteria:

1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)
4. Severe bronchoconstrictive lung disease
5. Prior hypersensitivity to study medication
6. Previously enrolled in pilot study
7. Pregnant
8. Incarcerated

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Adenosine

active comparator: Diltiazem

Interventions

adenosine

IV adenosine at standard doses for SVT (6 mg, 12 mg)

diltiazem

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Primary outcome measure

  • Feasibility outcome [ Time Frame: From enrollment to the end of ED encounter (up to 24 hours). ]
  • Feasibility outcome [ Time Frame: From enrollment to the end of ED encounter (up to 24 hours). ]
  • Feasibility outcome [ Time Frame: From enrollment to the end of ED encounter (up to 24 hours). ]

Central Contacts and Locations

Central contacts

Anne Zepeski, PharmD

(319) 356-2577anne-zepeski@uiowa.edu

Locations

University of Iowa Health Care

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Anne Zepeski, PhamD

651-207-9357anne-zepeski@uiowa.edu

More Information

Sponsor

Anne E. Zepeski

Last update posted

May 28, 2026

Last verified

May, 2026

Keywords

  • diltiazem
  • adenosine
  • emergency medicine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Anne E. Zepeski on 2026-05-28.